Details.
Patient assistance program covering Combivir, Cabenuva, Dovato, Epivir, Epzicom, Juluca, Lexiva, Retrovir, Rukobia, Selzentry, Tivicay and Tivicay PD, Triumeq and Triumeq PD, Trizivir, Viracept, and Ziagen. Financial eligibility is 500% FPL. Additional insurance and out-of-pocket expense requirements may apply for some applicants.